SCHEMBL2773403

SCHEMBL2773403

O=C1COC(=O)N1CCc1ccc(Br)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 3/20 0.46
MAPT P10636 3/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
PKM P14618 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
USP2 O75604 1/20 0.40
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA4 P22748 2/20 0.40
CA9 Q16790 2/20 0.40
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5164873 0.85 KMT2A (0.57) PIK3CGMAPTALDH1A1KMT2AMEN1
SCHEMBL2773670 0.83 CHRM5 (0.44) MAPTALDH1A1PKMKMT2AMEN1
SCHEMBL1383308 0.82 HRH3 (0.45) MAPTALDH1A1CYP3A4CYP2C9PKM
SCHEMBL2772180 0.81 ALDH1A1 (0.49) PIK3CGALDH1A1
SCHEMBL5145629 0.81 GSK3A (0.59) PIK3CGMAPTALDH1A1KMT2AMEN1
SCHEMBL2773255 0.81 PIK3CG (0.49) PIK3CGMAPTALDH1A1CYP3A4CYP2C9
SCHEMBL1379949 0.80 MAPT (0.37) PIK3CGMAPTALDH1A1CYP3A4CYP2C9
SCHEMBL22980462 0.79 CA1 (0.60) MAPTALDH1A1CYP3A4CYP2C9PKM
Iodide SCHEMBL2408901 0.78 MAPT (0.36) PIK3CGMAPTALDH1A1CYP3A4CYP2C9
SCHEMBL2771184 0.78 ALDH1A1 (0.46) PIK3CGALDH1A1CYP3A4L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590321-B1 ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY SANOFI AVENTIS (FR) 2010-04-28 EP disclosed
US-7632850-B2 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS SANOFI-AVENTIS (FR) 2009-12-15 US disclosed
US-20060014830-A1 Arylalkylcarbamate derivatives production and use thereof in therapy SANOFI-AVENTIS (FR) 2006-01-19 US disclosed
EP-1590321-A2 ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY Sanofi-Aventis (FR) 2005-11-02 EP disclosed
WO-2004067498-A2 ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY SANOFI-AVENTIS (FR) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014830-A1 Arylalkylcarbamate derivatives production and use thereof in therapy CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C5 PIK3CG 4177/4885MAPT 4791/4885ALDH1A1 2358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.